Among poor-risk genomic features, mutations in TP53 and complex karyotype (≥3 cytogenetic abnormalities) each occur in around 20% of older patients with AML (5) versus rates of 10% or lower in younger patients (6, 7). The gene discussed is TP53; the disease is acute myeloid leukemia.